[關(guān)鍵詞]
[摘要]
經(jīng)皮冠狀動脈介入術(shù)（PCI）是目前常見的冠心病的治療手段之一。血脂管理對于改善PCI術(shù)后的長期結(jié)局至關(guān)重要。冠心病PCI術(shù)后降脂藥物包括他汀類藥物、膽固醇吸收抑制劑、前蛋白轉(zhuǎn)化酶枯草溶菌素9（PCSK9）抑制劑和其他藥物?？偨Y(jié)了冠心病PCI術(shù)后降脂藥物的研究進(jìn)展，分析目前PCI術(shù)后藥物降脂治療中面臨的挑戰(zhàn)，比較不同降脂方案的優(yōu)劣，探索新型藥物的潛力，以期為研究者、醫(yī)療行業(yè)從業(yè)者提供研究思路和啟發(fā)。
[Key word]
[Abstract]
Percutaneous coronary intervention (PCI) is currently one of the common treatment methods for coronary heart disease. Blood lipid management is crucial for improving long-term outcomes after PCI surgery. Post PCI lipid-lowering drugs for coronary heart disease include statins, cholesterol absorption inhibitors, procalcitonin 9 (PCSK9) inhibitors, and other medications. This article summarizes the research progress on lipid-lowering drugs after PCI for coronary heart disease, analyzes the challenges faced in current PCI lipid-lowering treatment, compares the advantages and disadvantages of different lipid-lowering regimens, and explores the potential of new drugs, in order to provide research ideas and inspiration for researchers and medical industry practitioners.
[中圖分類號]
R973
[基金項(xiàng)目]
昆明市衛(wèi)生科技人才培養(yǎng)項(xiàng)目（千工程）[2023-SW（后備）-45]；云南中醫(yī)藥大學(xué)校院聯(lián)合基金項(xiàng)目（XYLH202355）
